Lucira Health, Inc. Form 8-K (Sept. 16, 2022)

Summary

Current report on Form 8-K of Lucira Health, Inc. dated September 16, 2022, reporting under Item 5.02, Departure of Directors or Certain Officers. The company states that on September 16, 2022 Erica J. Rogers, a Class II director, gave notice of resignation from the Board of Directors and all committees, effective immediately. The report states the resignation was not the result of a disagreement with the company or the Board on any matter relating to operations, policies or practices. Rogers had served on the Audit Committee and the Compensation Committee. The Board appointed Alison McCauley, an independent director, to the Audit Committee effective the same day. The signature block is Daniel George, Chief Financial Officer, dated September 22, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 16, 2022

Lucira Health, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware | 001-39976 | 27-2491037
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)
1412 62nd Street
Emeryville , California | 94608
(Address of Principal Executive Offices) | (Zip Code)
Registrant’s Telephone Number, Including Area Code: (510) 350-8071

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.001 per share | LHDX | NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Director

On September 16, 2022, Erica J. Rogers, a Class II director of the Board of Directors (the “Board”) of Lucira Health, Inc. (the “Company”), provided notice of her resignation as a member of the Board and all committees thereof, effective immediately. Ms. Rogers’s resignation was not the result of a disagreement with the Company or the Board on any matter relating to the Company’s operations, policies, or practices. Ms. Rogers served as a member of the Audit Committee of the Board (the “Audit Committee”) and the Compensation Committee of the Board.

In connection with and effective September 16, 2022, and following Ms. Rogers’s resignation, the Board appointed Alison McCauley, currently serving as an independent director of the Company, to the Audit Committee.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Lucira Health, Inc.
Date: | September 22, 2022 | By: | /s/ Daniel George
Daniel George, Chief Financial Officer

File and source

File

SEC_LHDX_8-K_filed2022-09-22_0000950170-22-018771.htm

Size

50,700 bytes

SHA-256

406eca8b80c63a61b140ed05c4ce3d71309bbbc66a7df88bdb5357c94c28d272

Our copy

SEC_LHDX_8-K_filed2022-09-22_0000950170-22-018771.htm

Original

www.sec.gov